Not Yet RecruitingNot Applicable

2-HOBA Supplementation in People With Elevated Lipoprotein(a)

United States10 participantsStarted 2025-11-01

Plain-language summary

The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels. The main questions it aims to answer are: Does 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood? Participants will: Take 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers

Who can participate

Age range18 Years – 69 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Males and females aged 18-69 years. * Elevated Lp(a) levels ≥ 90 mg/dL. * Able to provide informed consent and adhere to study schedules. * Willing to follow a physician-recommended diet during the study. Exclusion Criteria: * Pregnant, planning pregnancy during the study period, or currently breastfeeding. * Individuals with established cardiovascular disease * Planning major changes in diet or exercise routines. * Experienced \>20% weight change in the past 3 months. * Diagnosed with malabsorption syndrome or chronic diarrhea. * Abnormal liver, kidney, or thyroid function. * Drug or alcohol abuse within the past 6 months, or significant mental/psychological impairment. * Have known bleeding disorders (e.g., hemophilia). * Planned surgery during the study period. * Donated blood within the last 2 weeks or planning to donate during the study. * Require regular blood transfusions.

What they're measuring

Change in oxidized phospholipids (OxPL) on circulating lipoprotein(a)

Timeframe: 6 weeks

Trial details

NCT IDNCT07198009

SponsorThe Miriam Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-03

Contact for this trial

Wenliang Song, MD

4014449851 wsong@brownhealth.org